Clinical trial of recombinant human interferon α1b combined with aciclovir in the treatment of mononucleosis in children
Objective To observe the clinical efficacy and safety of recombinant human interferon α1b(rhIFN-α1b)aerosol inhalation combined with aciclovir in the treatment of monocytosis(IM)in children.Methods The children with IM were divided into control group and treatment group according to cohort method.The children were divided into control group and treatment group according to cohort method.The control group was treated with intravenous infusion of 10 mg·kg-1 aciclovir,q8 h.On this basis,the treatment group was treated with 2 μg·kg-1 rhIFN-α1b aerosol inhalation,q12 h.The course of treatment was 10 d.Clinical efficacy,clinical symptom improvement time,the levels of myocardial enzymes[creatine kinase(CK),creatine kinase isoenzyme(CK-MB)and glutamic oxalacetic transaminase(GOT)]and peripheral blood T lymphocyte subsets(CD3+,CD4+,CD8+and CD4+/CD8+),and the expression of Toll-like receptors(TLR7 and TLR9)and forkhead/wing spiral transcription factor 3(Foxp3)related mRNAs were compared between the two groups.Adverse drug reactions that occurred during treatment was statistically analyzed.Results A total of 47 cases were enrolled in the control group and 43 cases in the treatmet group.After 10 d of treatment,the clinical effective rates in the treatment group and the control group were 90.70％and 72.34％,with statistically significant difference between the groups(P＜0.05).The fever regression time in the treatment group and the control group were(4.43±1.27)and(5.28±1.82)d;the duration of atypical lymphocytes＜10％were(4.14±1.74)and(5.04±1.97)d;CK levels were(98.76±12.53)and(118.19±15.42)U·L-1;CK-MB levels were(18.41±2.15)and(23.67±3.79)U·L-1;CD4+/CD8+were 0.83±0.17 and 0.70±0.15;the relative expression levels of TLR7 mRNA were 1.12±0.35 and 1.33±0.40;the relative expression levels of TLR9 mRNA were 1.09±0.27 and 1.46±0.36;the relative expression levels of Foxp3 mRNA were 3.77±0.82 and 3.37±0.91.The differences were statistically significant(all P＜0.05).There was no significant difference in the incidence of adverse reactions between treatment group with control group(9.30％vs 6.38％,P＞0.05).Conclusion RhIFN-α1b aerosol inhalation combined with aciclovir is effective in the treatment of children with IM.The combined treatment can shorten clinical symptom relief time,alleviate myocardial injury and improve immune function,with high drug safety.
monocytosis injectionaciclovir injectionrecombinant human interferon α1bimmune functionefficacy evaluationsafety evaluation
国家科技期刊平台
NSTL
万方数据
